Format

Send to

Choose Destination
Br J Clin Pharmacol. 2004 Sep;58(3):303-9.

Statins and newly diagnosed diabetes.

Author information

1
Boston Collaborative Drug Surveillance Program, 11 Muzzey Street, Lexington, MA 02421, USA. sjick@bu.edu

Abstract

AIMS:

In order to evaluate a hypothesized protective effect of the use of HMG Co-A reductase inhibitors (statins) on the development of Type 2 diabetes, we conducted a nested case-control study based on data from the UK-based General Practice Research Database (GPRD).

METHODS:

We identified a population of adults 30-79 years of age between 1 January 1991 and 31 March 2002, who were being treated with a statin or who were diagnosed with hyperlipidaemia but were not being treated with a lipid-lowering drug. From this population we identified all incident cases of Type 2 diabetes. We conducted a nested case-control study encompassing 588 cases and 2063 matched controls.

FINDINGS:

We observed an adjusted odds ratio (OR) of 1.1 [95% confidence interval (CI) 0.8, 1.4] for current statin users compared with non-exposed subjects and adjusted ORs for pravastatin use alone and simvastatin use alone compared with non-exposed of 0.7 (95% CI 0.4, 1.2) and 1.0 (95% CI 0.7, 1.3), respectively. There was little evidence for a duration effect for simvastatin in these data, though there is a slight suggestion of a long-term protective effect with pravastatin.

CONCLUSION:

The current study results are most consistent with the conclusion that there is little if any protective effect of statins on the development of Type 2 diabetes.

PMID:
15327590
PMCID:
PMC1884569
DOI:
10.1111/j.1365-2125.2004.02142.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center